Neuroprotection - new promising treatment for glaucomatous optic neuropathy

摘要

@@ Glaucoma is the second leading cause of blindness worldwide, and also the most common optic neuropathy, affecting about 60 million people worldwide in its most common forms. This figure is expected to rise to 80 million by 2020[1-2]. In glaucoma, the ultimate cause of vision loss in glaucoma is thought to be retinal ganglion cell (RGC) death. Neuroprotection of RGC is therefore an important goal of glaucoma therapy[3].